Document Type : Review Article
Authors
1
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain-Shams University, Cairo 11566, Egypt
2
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt
3
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ahram Canadian University, 6th of October City, Giza 12566, Egypt
Abstract
Pyridazine-containing compounds have been identified as potent PARP1 inhibitors. The PARP is a family of enzymes essential for many cellular processes such as DNA repair, genomic stability, and apoptosis, also known as poly(ADP-ribose) synthetases and poly(ADP-ribose) transferases.PARP1 (Poly (ADP-ribose) polymerase 1) is an enzyme that plays a critical role in DNA repair and maintenance of genomic stability. The inhibition of PARP1 has emerged as a promising therapeutic strategy for the treatment of various cancers, especially those with defects in DNA repair pathways.
. Several diazine-containing compounds have been identified as potent PARP1 inhibitors, including Olaparib, Rucaparib, Niraparib, and Talazoparib. These compounds have shown promising results in preclinical and clinical studies, demonstrating their efficacies in the treatment of various cancers, including ovarian, breast, and pancreatic cancers.
In the following study, we’ll highlight some of the most recent diazine containing compounds and their role in the development of effective PAPR1 inhibitors.
Key words: Diazine, PARP1, DNA repair, Cancer
Keywords
)
View on SCiNiTO